Colgate-Palmolive Company (NYSE:CL) is one of the
12 Oversold Blue Chip Stocks to Buy According to Analysts.
On April 10, 2026, BofA analyst Peter Galbo lowered the price target on Colgate-Palmolive Company (NYSE:CL) to $102 from $105 and maintained a Buy rating ahead of Q1 results. Peter Galbo said the firm updated its estimates for organic sales and FY26 EPS to reflect delayed launch timing for Optic White in North America, which impacts near-term consumption, as well as a more conservative view on gross margins given rising oil-related input costs.
On April 9, 2026, RBC Capital lowered its price target on Colgate-Palmolive Company (NYSE:CL) to $102 from $104 and maintained an Outperform rating as part of a broader Q1 preview across consumer staples. RBC said the March quarter is expected to be stable but still characterized by a sluggish top-line environment, with investor focus shifting to forward guidance amid inflationary pressures and lingering effects from the Middle East conflict, despite the recent ceasefire.
Copyright: citalliance / 123RF Stock Photo
Last month, Colgate-Palmolive Company (NYSE:CL) announced that Christopher Boerner, CEO of Bristol-Myers Squibb, has been elected to its board of directors.
Colgate-Palmolive Company (NYSE:CL) manufactures and sells consumer products globally.
While we acknowledge the potential of CL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
